CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Grant or award Director acquired 61,475 shares (grant or award)
- 4 Grant or award Director acquired 61,475 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 122,950 shares (grant or award)
- 4 Open-market sale Director sold 11,200 shares at $2.34 ($26,181)
- 4 Open-market buy Director bought 1,724,137 shares at $2.90 ($4,999,997)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 344,828 shares (grant or award)
- 4 Grant or award President and CEO acquired 344,828 shares (grant or award)
- 4 Shares withheld for taxes Chief Technical Officer gave up 17,360 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 53,393 shares (to pay taxes)
- 4 Open-market buy CHIEF FINANCIAL OFFICER bought 190 shares at $3.60 ($683)
- 4 Grant or award Chief Technical Officer acquired 96,600 shares (grant or award)
- 4 Grant or award SVP, General Counsel acquired 41,800 shares (grant or award)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 29,400 shares (grant or award)
- 4 Grant or award Director acquired 211,973 shares (grant or award)
- 4 Grant or award EVP of R&D acquired 140,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 317,800 shares (grant or award)
- 4 Shares withheld for taxes EVP of R&D gave up 24,690 shares (to pay taxes)
- 4 Planned sale Director sold 18,640 shares at $2.70 ($50,317)
Page 4 of 14 · 275 filings